Search results
Showing 886 to 900 of 1397 results for 0
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
This indicator covers proportion of pregnant women accessing antenatal care who are seen for booking by 10 weeks and 0 days. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG81
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults.
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Bipolar, schizophrenia and other psychoses: cervical screening (IND85)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20
Pancreatic cancer in adults: diagnosis and management (NG85)
This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.
Thoracoscopic repair of congenital diaphragmatic hernia in neonates (HTG247)
Evidence-based recommendations on thoracoscopic repair of congenital diaphragmatic hernia in neonates. This involves inserting surgical instruments through small cuts in the chest, and then moving the abdominal organs out of the chest and repairing the diaphragm.
View recommendations for HTG247Show all sections
Sections for HTG247
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Patient Status Engine for wireless monitoring of vital signs (MIB271)
NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.